MedTrace Logo

Investigating Cardiovascular Adverse Events Related to Cancer Treatment

NCT03199300 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-12-11

No results posted yet for this study

Summary

Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown. Unraveling extreme cardiovascular toxic responses in cancer patients may help understand the pathophysiology of cardiovascular toxicity of these agents and help in understanding the more subtle, long-term cardiovascular side effects that affect a larger part of cancer survivors. With induced pluripotent stem cells we will obtain patient-derived cells to recapitulate and mimic and study pathological (cardiovascular) responses and (cardiovascular) toxicity in vitro.

Conditions

  • Toxicity Due to Chemotherapy
  • Cardiovascular Morbidity
  • Cancer, Treatment-Related

Interventions

DRUG

Anthracyclines

Chemotherapy regimen containing anthracyclines.

DRUG

Trastuzumab

Systemic treatment including trastuzumab.

DRUG

Cisplatin

Chemotherapy including cisplatin.

DRUG

Bleomycin

Chemotherapy including bleomycin.

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • J.A. Gietema, MD, PhD · University Medical Center Groningen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-12
Primary Completion
2025-02-06
Completion
2027-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03199300 on ClinicalTrials.gov